Skip to content

Effect of Exercise Training in Patients With Pulmonary Hypertension

Effect of Exercise Training in Arterial and Chronic Thromboembolic Pulmonary Hypertension in Switzerland and Standardization With European Countries

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02558582
Enrollment
32
Registered
2015-09-24
Start date
2015-09-01
Completion date
2023-12-31
Last updated
2022-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, Pulmonary

Keywords

Pulmonary arterial hypertension, Chronic thromboembolic pulmonary hypertension, Rehabilitation, Oxygen

Brief summary

Pulmonary Hypertension (PH) is a serious disease with a dismal prognosis when left untreated. Advances in medical therapy have improved survival according to recent registries and systematic reviews, but are associated with high healthcare costs. Earlier studies in Heidelberg, Germany showed good evidence for the effect of exercise training on improving exercise performance, quality of life and pulmonary hemodynamics in patients with pulmonary hypertension. The main objectives of the present project are: 1. to investigate the quality of the implementation of a standardized 3 week in-hospital exercise training program on markers of outcome and disease severity in PH-patients in Switzerland immediately after training and after 3 and 12 month. 2. to look whether training with hyperoxia vs. standard care might be more effective. This is a multicentre, randomized parallel-group trial where the intervention rehabilitation is delayed in one group so that they can serve as standard care controls for the others. In a nested single-centre randomized-controlled trial patent will additionally be randomized to receive either usual rehabilitation (UR) or rehabilitation with standardized supplemental oxygen therapy (SSOT) during nights and ergometer training. Patients will receive a PH specific rehabilitation program during 3 weeks followed by an instructed home-based training program for 12 weeks. Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights upon written informed consent.

Interventions

The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.

BEHAVIORALrespiratory and exercise therapy with supplemental oxygen

The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training. Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights.

Sponsors

University of Zurich
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* WHO functional class II-IV * PH diagnosed by right heart catheter showing: * Baseline mean pulmonary arterial pressure (mPAP) ≥ 25 mmHg * Baseline pulmonary vascular resistance (PVR) \> 240 dyn x s x cm-5 * Baseline pulmonary capillary wedge pressure (PCWP) ≤ 15 mm Hg * Patients receiving maximal PH therapy including intensified treatment with diuretics and who have been stable for 2 months before entering the study * PH target therapy should not be expected to change during the entire 15-week study period * Negative pregnancy test (β-HCG) at the start of the trial * Able to understand and willing to sign the Informed Consent Form

Exclusion criteria

* PH due to significant left heart disease (Wedge ≥ 15mmHg) or lung disease (FEV1 ≤ 60% predicted) * Pregnancy at study onset * Walking disability * Any change in disease-targeted therapy within the last 2 months * Any subject who is scheduled to receive another investigational drug during the course of this study * Any other relevant concomitant disease * Systolic blood pressure \< 85 mmHg * History or suspicion of inability to cooperate adequately

Design outcomes

Primary

MeasureTime frame
Constant cardiopulmonary exercise testing change in endurance timeChange from Baseline to 15 weeks
6 Minute walking testChange from Baseline to 15 weeks

Secondary

MeasureTime frameDescription
Sit-to-Stand (physiological parameter)Baseline, 3 weeks, 15 weeks, 6 and 12 monthsNumber of Sit-to-Stand performed in 1 minute
Stair Ascent (physiological parameter)Baseline, 3 weeks, 15 weeks, 6 and 12 monthsForce, Power and Time needed to climb 5 steps
Cognitive function (questionnaire)Baseline, 3 weeks, 15 weeks, 6 and 12 monthsTrail Making Test A & B, Stroop 1-3, 5 point test
Functional class (scale)Baseline, 3 weeks, 15 weeks, 6 and 12 months
Lung function (physiological parameter)Baseline, 3 weeks, 15 weeks, 6 and 12 monthsForced vital capacity and liters in 1 second, Total lung capacity, diffusion of carbon dioxide
Daily activity (energy expenditure, steps per day, sleep time and efficiency, lying down time, physical activity level, metabolic equivalent units)Baseline, 3 weeks, 15 weeks, 6 and 12 monthsActigraphy
Hemodynamic (physiological parameter)Baseline, 3 weeks, 15 weeks, 6 and 12 monthsPulmonary artery pressure, cardiac output
Quality of Life (questionnaire)Baseline, 3 weeks, 15 weeks, 6 and 12 monthsMinnesota living with heart failure questionnaire, Camphor, short form 36 item

Other

MeasureTime frame
Hospitalisation daysBaseline, 3 weeks, 15 weeks, 6 and 12 months

Countries

Switzerland

Contacts

Primary ContactSilvia Ulrich Somaini, PD Dr.
silvia.ulrich@usz.ch0041442552220
Backup ContactStéphanie Saxer, MSc
stephanie.saxer@usz.ch0041442552220

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026